Technical Data Sheet

InVivoSIM bispecific anti-human PD-L1 x VEGF-A (Pumitamig Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIMB0099**
Clone:	**Pumitamig**
Isotype:	Human IgG1, κ
Recommended Isotype Control(s):	RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Reported Applications:	*in vivo* functional assays *in vitro* functional assays ELISA
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 μm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This Pumitamig biosimilar antibody uses the same variable regions as the therapeutic antibody Pumitamig (formerly BNT327), making it ideal for research use. Pumitamig is a bispecific IgG1 antibody that simultaneously targets human PD-L1 and VEGF-A, integrating immune checkpoint blockade with anti-angiogenic activity in a single molecule. By binding PD-L1, Pumitamig disrupts PD-1/PD-L1–mediated inhibitory signaling and restores T-cell activation within the tumor microenvironment. Concurrently, binding to VEGF-A inhibits VEGF signaling, reducing tumor angiogenesis, vascular permeability, and VEGF-driven immunosuppression. This dual-targeting strategy is designed to enhance antitumor immune responses by improving immune cell infiltration, normalizing tumor vasculature, and counteracting VEGF-associated resistance mechanisms to checkpoint inhibition. Pumitamig has shown promising clinical activity across multiple solid tumor indications, particularly in immunologically “cold” tumors where combined angiogenesis inhibition and immune activation

may be advantageous. This Pumitamig biosimilar is well suited for studying PD-L1 biology, VEGF-mediated angiogenesis, immune–vascular crosstalk, tumor microenvironment remodeling, and for use as a research tool to benchmark the therapeutic antibody's mechanism of action in pre-clinical experimental systems.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/simb0099?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com